Solvonis Therapeutics has shown its experimental esketamine dissolvable film delivers the drug into the bloodstream at levels comparable to Spravato, an FDA-approved depression treatment. This data meets a critical FDA requirement, allowing Solvonis to proceed with human trials for its alcohol addiction medication. The company plans to start mid-stage clinical trials within two years, targeting a large market of 15 million Americans with moderate-to-severe alcohol use disorder. This development offers hope for a condition with few effective pharmaceutical treatments.
Trading in two TOBA Investments funds, Bonds and Equities, will be suspended from June 22 to June 25, 2026, due to their transfer to Investeringsforeningen IA Invest. After the transfer, the Equities fund will be renamed TA Globale Aktier and the Bon...
Bavarian Nordic A/S has repurchased 331,973 shares at an average price of DKK 181.11, totaling DKK 60.1 million, as part of its share buyback program launched on June 2, 2026. The program allows the company to buy back shares worth up to DKK 150 mill...
Jyske Bank is conducting a share buyback program running from February 5, 2026, to January 29, 2027, with a maximum value of DKK 3 billion. As of the latest transactions in mid-June 2026, the bank has repurchased shares worth approximately DKK 1.17 b...
Jyske Bank continues its share repurchase program running from February 2026 to January 2027, acquiring shares valued at approximately DKK 1.17 billion so far. The bank has bought a total of 1,288,703 treasury shares, representing 2.21% of its share ...
DNO ASA announced that an appraisal well has further defined the 2023 Carmen gas-condensate discovery in the Norwegian North Sea, increasing recoverable resources to an estimated 21–107 million barrels of oil equivalent. Most volumes were found in th...
